Based on these data, as well as on the synergistic antitumor activity of immunotherapy and chemotherapy in other advanced neoplasms (such as non-small cell lung cancer [165,166]) and in patients with limited-stage TNBC [161,167], two randomized, phase III trials investigated whether adding the anti-PD-L1 monoclonal antibody atezolizumab to first-line chemotherapy is able to improve clinical outcomes in mTNBC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.